🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT01548352
Active, not recruiting Observational

BAsel Syncope EvaLuation (BASEL IX) Study

NCT01548352 · tracked via the Priya Life Science Italy tracker
Sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Started
2010-04
Last updated
2025-04-15

Condition(s) studied

Syncope

Study summary

Syncope is a major health problem. In the emergency department (ED), the management of patients with syncope still remains a clinical challenge because underlying diseases and prognosis can be extremely various. Structural heart disease and primary electrical disorders are major risk factors for sudden cardiac death and mortality in patients with syncope. In contrast, patients with reflex syncope and exclusion of structural heart disease have an excellent prognosis.

Therefore The investigators test the hypothesis that the use of a meticulous patient history, clinical examination and novel biomarkers can improve the rapid and accurate diagnosis of cardiac syncope in patients presenting to the ED and is able to improve risk stratification regarding adverse outcomes.

The prospective multicenter cohort study is designed to enroll 720 patients presenting with transient loss of consciousness within the last 12 hours to the ED. Blood samples for the measurement of novel biomarkers will be obtained at presentation.

All patients will be contacted by phone at 6, 12 and 24 months to determine major adverse events (death, resuscitation, recurrence of syncope, hospitalization for syncope).

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients presenting to the emergency department * Age \> 40 years * Syncope within the last 12 hours * Written informed consent Exclusion Criteria: * Age \< 40 years * Patients without loss of consciousness and with certain neurological causes (e.g. recurrent epilepsy, hemiplegia at presentation) * No written informed consent

Primary outcome measure(s)

Trial sites (15)

FacilityCityRegionStatus
Baylor College of Medicine Houston Texas
Instituto Cardiovascular de Buenos Aires Buenos Aires Argentina
Royal Brisbane and Women's hospital Brisbane Australia
Klinikum Nürnberg Nuremberg Bavaria
Sant'Andrea Hospital Rome Italy
Christchurch Hospital Christchurch New Zealand
Medical University of Silesia Zabrze Poland
Hospital del Mar Barcelona Spain
Hospital Clinic of Barcelona Barcelona Spain
Hospital Universitario Clínico San Carlos Madrid Spain
Kantonsspital Baselland Liestal Basel-Landschaft
Spital Lachen Lachen Canton of Schwyz
University Hospital Basel Basel Switzerland
Luzern Kantonsspital Lucerne Switzerland
University Hospital Zurich Zurich Switzerland

More University Hospital, Basel, Switzerland trials in Italy

Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators. Recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema Recruiting
The OPBC-07/microNAC Study Active, not recruiting
Risk of Recurrent CeAD After Pregnancy Recruiting
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery Recruiting

Other trials for the same condition

Global Approach to Faint and Falls Recruiting
Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) Recruiting
Syncope-Asystole Latency Time in Tilt Table Test: The SALT-TILT Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01548352 on ClinicalTrials.gov ↗ ← All trials in Italy